Use should be restricted to clinical trials; other options are recommended for non-severe COVID-19, including nirmatrelvir–ritonavir (Paxlovid) and remdesivir.
Health research uses a wide variety of terminology when it comes to Canada Black population and that lack of specificity has the potential to hamper key research.